More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings climbed 65% on higher demand for its clinical R&D services and data analysis. Service revenue rose 27% to $422.1M, with newly-acquired Liquent contributing $400K in the quarter. Backlog at the end of December was approximately $4.54B, up 21.4% Y/Y. It also raises FY guidance, now expecting to earn $1.48 to $1.56 per share, with consolidated service revenue between $1.695B and $1.710B. Shares +3.4% AH.
More on Parexel (PRXL): FQ2 beats across the board on a 26% jump in total revenue. Net earnings...
From other sites
at CNBC.com (Dec 24, 2014)
at CNBC.com (Oct 30, 2014)
at CNBC.com (Aug 19, 2013)
at CNBC.com (May 13, 2013)
at CNBC.com (Jan 31, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs